Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
CONCLUSIONS: The LNG-IUS probably slightly reduces the incidence of benign endometrial polyps and endometrial hyperplasia in women with breast cancer taking tamoxifen. At 12 and 24 months of follow-up, the LNG-IUS probably increases abnormal vaginal bleeding or spotting among women in the treatment group compared to those in the control. Data were lacking on whether the LNG-IUS prevents endometrial cancer in these women. There is no clear evidence from the available RCTs that the LNG-IUS affects the risk of breast cancer recurrence or breast cancer-related deaths. Larger studies are necessary to assess the effects of the LNG-IUS on the incidence of endometrial cancer, and to determine whether the LNG-IUS might have an impact on the risk of secondary breast cancer events.
PMID: 33348436 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Romero SA, Young K, Hickey M, Su HI Tags: Cochrane Database Syst Rev Source Type: research
More News: Bleeding | Breast Cancer | Cancer | Cancer & Oncology | Cancer of the Uterus | Databases & Libraries | Endocrine Therapy | Endometrial Biopsy | Endometrial Cancer | General Medicine | Hysteroscopy | Mirena | Nurses | Nursing | OBGYN | Pathology | Polyps | Reproduction Medicine | Study | Tamoxifen | Women